Differential outcome of patients with MDS and AML after HMA failure based on induction strategy
| . | MDS . | AML . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Global (n = 307) . | 7+3 (n = 173) . | IDAC (n = 44) . | PNA (n = 90) . | P . | Global (n = 59) . | 7+3 (n = 30) . | IDAC (n = 12) . | PNA (n = 17) . | P . |
| Response, CR+CRi% | 41 | 39 | 64 | 34 | .04 | 32 | 63 | 25 | 21 | .43 |
| 8-wk mortality, % | 6.5 | 8.7 | 2.3 | 4.4 | .19 | 15.3 | 16.7 | 0 | 23.5 | .21 |
| Median OS, mo | 10.8 | 9.3 | 10.9 | 12.9 | .52 | 6.0 | 8.0 | 6.9 | 4.4 | .06 |
| Median CIR, mo | 11.6 | 11.3 | 12.5 | 14.1 | .60 | 14.4 | 16.6 | 13.0 | 13.9 | .15 |
| Responders undergoing Allo, % | 39.7 | 37.3 | 64.3 | 22.6 | <.01 | 42 | 42 | 67 | 25 | .54 |
| . | MDS . | AML . | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| . | Global (n = 307) . | 7+3 (n = 173) . | IDAC (n = 44) . | PNA (n = 90) . | P . | Global (n = 59) . | 7+3 (n = 30) . | IDAC (n = 12) . | PNA (n = 17) . | P . |
| Response, CR+CRi% | 41 | 39 | 64 | 34 | .04 | 32 | 63 | 25 | 21 | .43 |
| 8-wk mortality, % | 6.5 | 8.7 | 2.3 | 4.4 | .19 | 15.3 | 16.7 | 0 | 23.5 | .21 |
| Median OS, mo | 10.8 | 9.3 | 10.9 | 12.9 | .52 | 6.0 | 8.0 | 6.9 | 4.4 | .06 |
| Median CIR, mo | 11.6 | 11.3 | 12.5 | 14.1 | .60 | 14.4 | 16.6 | 13.0 | 13.9 | .15 |
| Responders undergoing Allo, % | 39.7 | 37.3 | 64.3 | 22.6 | <.01 | 42 | 42 | 67 | 25 | .54 |
CR, complete remission; CRi, complete remission with incomplete blood count recovery; Responders undergoing Allo, percentage of responders to induction chemotherapy undergoing allogeneic transplant.